Bing

SEARCH HISTORY

Palatin Technologies (NYSE:PTN)‘s stock had its “buy” rating restated by Roth Capital in a research note issued on Friday, AnalystRatings.Net reports. They currently have a $4.00 target price on the biopharmaceutical company’s stock. Roth Capital ...
Ticker Report · 4 hours ago
Palatin Technologies
Currently, 5.2% of the shares of the stock are short sold. PTN has been the subject of a number of recent research reports. Analysts at Roth Capital set a $4.00 price target on shares of Palatin Technologies and gave the company a “buy” rating in a ...
sleekmoney.com · 6/25/2015
As information was released (via internet stock message boards) and it became evident by astute traders that another company (privately held Sprout Pharmaceuticals) owned the rights to flibanserin, PTN stock price eroded for the remainder of the day and ...
Seeking Alpha · 6/19/2015
Palatin Technologies
More from Bing News
NEW YORK (TheStreet) -- Palatin Technologies (PTN - Get Report) shares up 34.52% to $1.21 in trading on Friday after an Food and Drug Administration advisory panel voted 18-6 to approve a drug called flibanserin that treats low libido in women. While ...
The Street · 6/5/2015
Research analysts at Roth Capital set a $4.00 price target on shares of Palatin Technologies (NYSE:PTN) stock in a report released on Friday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s price ...
wkrb13.com · 6/5/2015
... ALEXION PHARMACEUTICALS INC (ALXN): Free Stock Analysis Report ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report ALKERMES PLC ORD (ALKS): Free Stock Analysis Report PALATIN TECH INC (PTN): Free Stock Analysis …
Yahoo Finance · 4/2/2014
NEW YORK — Fears that Greece’s troubles could spread through the global financial system shook markets on Monday, giving US stocks their worst day of the year. Investors fled from stocks in Europe and the …
The Boston Globe · 6/30/2015
debt crisis
Palatin Technologies (NYSE: PTN) 25.6% HIGHER; an FDA panel voted to support approval of Sprout's female libido drug. Notably, Palatin's Bremelanotide is in advanced trials to treat female sexual dysfunction. Esterline Technologies (NYSE: ESL) 10.1% …
StreetInsider · 6/4/2015
Palatin Technologies (AMEX:PTN) announced Thursday morning that its Phase IIb trial for bremelanotide met its primary endpoint, as well as secondary endpoints, for the treatment of female sexual dysfunction (FSD). Bremelanotide is Palatin's primary value ...
Reuters · 11/8/2012
Palatin Technologies Inc. ( PTN) was a big mover last session, with shares rising nearly 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the ...
NASDAQ · 3/20/2014